Employees: 1,271
Size Hunan Er-Kang Pharmaceutical (300267.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $829M, the 2515th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.72 on 18 Nov 2026.
Performance Over six months the shares fell 40.2%, against -8.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue fell 14.4% over the last twelve months (peer median +3.8%); the operating margin is -29.2% (peer median 6.7%).
Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.1× (7th most expensive of 18).
Capital Return on invested capital runs 11.6 points below its cost of capital (7.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.11B | CN¥1.16B | CN¥1.13B | CN¥1.77B | CN¥1.86B |
| Revenue growth | — | +2% | -36% | -5% | — |
| Gross profit | CN¥414M | CN¥242M | CN¥210M | CN¥241M | CN¥278M |
| EBITDA | n/a | CN¥140M | CN¥103M | -CN¥10.7M | CN¥172M |
| Net income | -CN¥347M | -CN¥380M | -CN¥373M | -CN¥195M | CN¥45.9M |
| Free cash flow | -CN¥161M | CN¥97.5M | -CN¥27.0M | -CN¥77.0M | CN¥121M |
| Capital expenditure | CN¥237M | CN¥164M | CN¥196M | CN¥238M | CN¥173M |
| Total debt | CN¥702M | CN¥602M | CN¥517M | CN¥363M | CN¥401M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300267.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.5% | -7.7% | 10th lowest of 21 |
| 6-month return | -40.2% | -8.1% | 2nd lowest of 20 |
| Distance from 52-week high | -46.8% | -37.2% | 6th lowest of 21 |
| Revenue growth (TTM) | -14.4% | +3.8% | 2nd lowest of 19 |
| Operating margin | -29.2% | 6.7% | 5th lowest of 19 |
| EV / Sales | 4.7× | 3.1× | 7th most expensive of 18 |
| ROIC minus cost of capital | -11.6 pp | -2.3 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |